title: Anthracycline dose intensification in young adults with acute myeloid leukemia.
abstract: The initial treatment for acute myeloid leukemia (AML) has remained largely unchanged for nearly 40 years. Our growing understanding of the molecular pathology of AML has resulted in improved measures to risk stratify patients by recurrent cytogenetic and molecular abnormalities without marked advancement in its initial treatment. The most common regimen consists of a 3-day course of an anthracycline and a 7-day infusion of cytarabine. This regimen has been employed across the globe in various iterations for many years with modest improvements in results yet this remains the first choice for the treatment of younger adults with AML. Despite this, the chemotherapeutic agents in this regimen are only now being fully understood. Recent evidence has suggested that dose intensification of anthracycline in young adults has a significant survival benefit. In this paper we review the evidence behind the use of anthracyclines in the initial induction of AML in younger adults focusing on the choice and dose of this long used drug combination.
authors.forename: Eric
authors.initials: E
authors.lastname: Padron
authors.forename: Hugo
authors.initials: H
authors.lastname: Fernandez
keywords: acute myeloid leukemia; dose intensification; induction therapy
references.citation: Br J Clin Pharmacol. 1987 Mar;23(3):303-10
references.pmid: 3471265
references.citation: Biochem Biophys Res Commun. 1976 Apr 5;69(3):744-50
references.pmid: 944579
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1856-62
references.pmid: 20212254
references.citation: Blood. 2007 Dec 15;110(13):4476-9
references.pmid: 17827387
references.citation: J Natl Cancer Inst. 2006 Dec 20;98(24):1794-806
references.pmid: 17179481
references.citation: J Clin Oncol. 2010 Feb 10;28(5):808-14
references.pmid: 20048183
references.citation: Leukemia. 1997 Oct;11(10):1605-9
references.pmid: 9324277
references.citation: Cancer Res. 1972 Oct;32(10):2023-6
references.pmid: 4562823
references.citation: Eur J Cancer Clin Oncol. 1987 Jul;23(7):1041-5
references.pmid: 3478198
references.citation: Invest New Drugs. 1984;2(4):375-9
references.pmid: 6595242
references.citation: Biochem Pharmacol. 1978;27(14):1881-2
references.pmid: 708470
references.citation: Blood. 1987 Mar;69(3):744-9
references.pmid: 3469002
references.citation: Cancer Res. 1977 Dec;37(12):4523-8
references.pmid: 922737
references.citation: J Clin Oncol. 2011 Mar 10;29(8):979-85
references.pmid: 21282541
references.citation: Blood. 2004 Oct 15;104(8):2467-74
references.pmid: 15142880
references.citation: Blood. 1991 Apr 15;77(8):1666-74
references.pmid: 2015395
references.citation: Br J Haematol. 1998 Oct;103(1):100-9
references.pmid: 9792296
references.citation: Cancer Chemother Rep. 1973 Nov-Dec;57(4):485-8
references.pmid: 4586956
references.citation: Am J Epidemiol. 1988 Mar;127(3):419-39
references.pmid: 3277397
references.citation: Blood. 1981 Dec;58(6):1203-12
references.pmid: 6946847
references.citation: Blood. 1981 Jun;57(6):1068-73
references.pmid: 6939452
references.citation: Blood. 2001 Sep 15;98(6):1752-9
references.pmid: 11535508
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1446-54
references.pmid: 18316568
references.citation: Leuk Res. 2009 Jan;33(1):129-39
references.pmid: 18676016
references.citation: Hematology Am Soc Hematol Educ Program. 2010;2010:56-61
references.pmid: 21239771
references.citation: N Engl J Med. 1979 Jul 5;301(1):1-5
references.pmid: 286882
references.citation: Blood. 2011 Feb 24;117(8):2358-65
references.pmid: 20693429
references.citation: Clin Pharmacol Ther. 1986 Dec;40(6):643-9
references.pmid: 3465490
references.citation: Blood. 1992 Dec 15;80(12):2977-82
references.pmid: 1467513
references.citation: Blood. 1999 Jun 15;93(12):4116-24
references.pmid: 10361108
references.citation: Blood. 1996 Oct 15;88(8):2841-51
references.pmid: 8874180
references.citation: Cancer Res. 1989 Jan 15;49(2):477-81
references.pmid: 2910465
references.citation: Br J Haematol. 1997 Oct;99(1):76-83
references.pmid: 9359506
references.citation: Leukemia. 1990 Mar;4(3):177-83
references.pmid: 2179638
references.citation: J Clin Oncol. 1988 Feb;6(2):213-7
references.pmid: 3422260
references.citation: Blood. 1997 May 1;89(9):3323-9
references.pmid: 9129038
references.citation: Cancer Treat Rep. 1982 May;66(5):1139-43
references.pmid: 7083216
references.citation: Ann Intern Med. 1984 Nov;101(5):581-8
references.pmid: 6385797
references.citation: J Clin Oncol. 1992 Jul;10(7):1103-11
references.pmid: 1607916
references.citation: J Clin Oncol. 1994 Dec;12(12):2535-42
references.pmid: 7989927
references.citation: Cancer Res. 1985 Mar;45(3):1408-12
references.pmid: 3855696
references.citation: N Engl J Med. 1994 Oct 6;331(14):896-903
references.pmid: 8078551
references.citation: Blood. 2009 Jul 2;114(1):148-52
references.pmid: 19398719
references.citation: J Clin Oncol. 2004 Nov 1;22(21):4290-301
references.pmid: 15514371
references.citation: Blood. 1982 Aug;60(2):454-62
references.pmid: 6953986
references.citation: N Engl J Med. 2009 Sep 24;361(13):1249-59
references.pmid: 19776406
references.citation: Blood. 1992 Jan 15;79(2):313-9
references.pmid: 1730080
references.citation: Cancer Causes Control. 2008 May;19(4):379-90
references.pmid: 18064533
references.citation: Ann Intern Med. 1980 Jul;93(1):17-21
references.pmid: 6930826
references.citation: Blood. 2009 Jul 30;114(5):937-51
references.pmid: 19357394
references.citation: Blood. 2001 Oct 15;98(8):2301-7
references.pmid: 11588023
references.citation: J Clin Oncol. 1985 Apr;3(4):562-92
references.pmid: 3884748
references.citation: Leukemia. 1989 Feb;3(2):115-21
references.pmid: 2911205
references.citation: J Clin Oncol. 2009 Nov 10;27(32):5397-403
references.pmid: 19826132